Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
2019 · New England Journal of Medicine · 5,793 citations
https://doi.org/10.1056/nejmoa1811744
C
Carol A. Pollock
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
642
Papers
27.5K
Citations
79
h-index
309
i10-index
Carol A. Pollock is an academic researcher. The author has contributed to research in topics: Diabetes Treatment and Management & Chronic Kidney Disease and Diabetes & Dialysis and Renal Disease Management. The author has an h-index of 79, co-authored 546 publications.
ORCID: 0000-0001-7167-6495Papers by this author
worksGlobal kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
2017 · The Lancet · 895 citations
https://doi.org/10.1016/s0140-6736(17)30788-2
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
2016 · Kidney International · 468 citations
https://doi.org/10.1016/j.kint.2015.10.002
Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial
2015 · Intensive Care Medicine · 225 citations
https://doi.org/10.1007/s00134-015-3827-9
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
2020 · Kidney International · 150 citations
https://doi.org/10.1016/j.kint.2020.10.042
Thioredoxin interacting protein (TXNIP) regulates tubular autophagy and mitophagy in diabetic nephropathy through the mTOR signaling pathway
2016 · Scientific Reports · 130 citations
https://doi.org/10.1038/srep29196
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat